Gilead Sciences and Tubulis Agreement
Gilead Sciences (GILD) and Tubulis announced that they entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms.
The companies will collaborate to . . .
This content is for paid subscribers.
Impacting News
December 4, 2024